Clinical research published since the first evidence-based review on the role of hematopoietic stem cell transplantation (SCT) in the treatment of acute lymphoblastic leukemia (ALL) in adults is presented and critically evaluated in this update. Treatment recommendations changed or modified based on new evidence include: (1) myeloablative allogeneic SCT is an appropriate treatment for adult (\35 years) ALL in first complete remission for all disease risk groups; and (2) reduced-intensity conditioning may produce similar outcomes to myeloablative regimens. Treatment recommendations unchanged or strengthened by new evidence include: (1) allogeneic SCT is recommended over chemotherapy for ALL in second complete remission or greater; (2) allogeneic is superior to autologous SCT; and (3) there are similar survival outcomes after related and unrelated allogeneic SCT. New treatment recommendations based on new evidence include: (1) in the absence of a suitable allogeneic donor, autologous SCT may be an appropriate therapy, but results in a high relapse rate; (2) it is appropriate to consider cord blood transplantation for patients with no HLA well-matched donor; and (3) imatinib therapy before and/or after SCT (for Ph1 ALL) yields significantly superior survival outcomes. Areas of needed research in the treatment of adult ALL with SCTwere identified and presented in the review.
INTRODUCTION
In 1999, the American Society for Blood and Marrow Transplantation (ASBMT) began the development of systematic evidence-based reviews (EBRs) and position statements on the effectiveness of autologous and allogeneic hematopoietic stem cell transplantation (SCT) for specific diseases. In 2009, the ASBMT EBR Steering Committee determined that previously published reviews should be updated regularly at approximately 5-year intervals. This constitutes the first update of the adult acute lymphoblastic leukemia (ALL) EBR originally published in 2006.
UPDATE OF THE ADULT ALL EBR
This adult ALL EBR update adheres to the methodology and grading systems presented in Appendix A (online only). In the original adult ALL EBR [1] , each article was summarized in detail in the text, accompanied by summary tables comparing study designs and patient outcomes. To streamline this update, a concise summary of outcomes is provided in each section of text, whereas descriptions of the study design, patient population, and clinical outcomes of each article are presented in detailed summary tables.
Evidence in each section is presented with the highest quality studies first; studies of equal quality are presented in descending order by study population size. New evidence is provided first in each table, followed by the highest quality studies (ratings 111 and 211) used to make treatment recommendations in the original adult ALL EBR. Both Level 1 and Level 2 evidence is presented in the tables for each study that provided biologic assignment (donor versus no donor) and randomized (autologous SCT versus chemotherapy) results. Table 1 contains the summary of consensus treatment recommendations made by the expert panel based on the summarized evidence on the use of SCT to treat adult ALL. The consensus process is detailed in Appendix A (online only) and involves a teleconference during which panelists critically discuss the evidence for each section of the review and develop treatment recommendations rated according to the categories in Table 1 and in Appendix A, Table 2 . Table 1 presents new treatment recommendations based on the adult ALL evidence published since January 2005. In addition, the treatment recommendations from the original adult ALL EBR are incorporated into the respective tables when applicable. It is indicated whether the new evidence strengthens, modifies, or does not change the original recommendation. Four treatment options included in the original adult ALL EBR treatment recommendations table were removed in this update for the following reasons. First, there were no new studies of purged or unpurged autologous SCT, which is no longer relevant based on current treatment preferences. In addition, noncomparative studies of related and unrelated allogeneic SCT were included in the original adult ALL EBR because there were no comparative studies of these techniques; however, in this update, comparative evidence is presented, making these separate categories unnecessary. Additional evolution of SCT techniques, including advances in donor selection through highresolution HLA typing and matching and in supportive care, all influence the current findings and limit their direct comparability to earlier reports.
TREATMENT RECOMMENDATIONS

TRANSPLANTATION VERSUS CHEMOTHERAPY FOR ADULT ALL
There were 11 studies published since the original adult ALL EBR, and briefly summarized below, which compared the efficacy of transplantation versus chemotherapy as treatment for adult ($18 years) patients with ALL in first complete remission (CR1). Table 2 presents a detailed summary of the study designs, patient populations, and outcomes from this new evidence. Six high-quality (111 to 211) studies comparing transplantation versus chemotherapy in CR1 that were used to make treatment recommendations in the original adult ALL EBR are also presented in Table 2 . Table 3 presents two studies published since January 2005 that compared transplantation versus chemotherapy as treatment for relapsed or refractory adult ALL. The quality ratings for these two studies were 211 and 21. There were no studies in the original adult ALL EBR that compared transplantation versus chemotherapy for refractory or relapsed ALL, or for ALL in second complete remission (CR2).
Transplantation versus Chemotherapy for Adult ALL in CR1
The 11 new studies presented in Table 2 provided 15 analyses, including four meta-analyses, four randomized autologous SCT versus chemotherapy, four donor versus no donor, and three allogeneic SCT versus chemotherapy 6 imatinib for the treatment of adult ALL in CR1. The quality ratings of these studies ranged from 111 to 21.
Meta-analyses
To briefly summarize, in a meta-analysis of aggregate data from 13 studies, Ram et al. [2] reported a significant reduction in all-cause mortality in favor of adult ALL patients in CR1 who underwent an allogeneic SCT versus chemotherapy alone or an autologous SCT in studies which analyzed data by intention to treat. In a meta-analysis of individual patient data from four studies, Orsi et al. [3] reported a significant difference in event-free survival (EFS) in favor of ALL patients in CR1 who had a donor versus those with no donor. Similarly, in a meta-analysis of aggregate data from seven studies, Yanada et al. [4] reported a significant advantage in overall survival (OS) for those patients with a donor versus those with no donor. In a meta-analysis of individual patient data from three studies, Dh edin et al. [5] found no significant difference in 10-year disease-free survival (DFS) or OS between ALL patients in CR1 who underwent autologous SCT versus those who received chemotherapy alone.
Autologous SCT versus Chemotherapy
In a prospective, multicenter study (UKALL XII/ ECOG 2993) by Goldstone et al. [6] , 456 patients were randomized to receive an autologous SCT or chemotherapy alone. A significant difference in 5-year EFS and OS was reported in favor of chemotherapy for standard or high-risk patients. Marks et al. [7] analyzed a subset of T-lineage ALL patients from the UKALL XII/ECOG 2993 trial and found no significant difference in 5-year OS between those randomized to autologous SCT versus chemotherapy alone. Ribera et al. [8] found no significant difference in 5-year DFS or OS between high-risk ALL patients in CR1 randomized to autologous SCT versus chemotherapy alone. Similarly, Hunault et al. [9] found no significant difference in 7-year relapse-free (Table 6 ) Available data suggest imatinib therapy before and/or after SCT yields significantly superior outcomes in OS and LFS. Ongoing studies using other tyrosine kinase inhibitors may enhance this recommendation.
Comparison of induction therapies before SCT
No treatment recommendation based on new data published since the original review 1++ 40 (Table 6) There are insufficient data to make a treatment recommendation regarding the benefit of any one induction regimen.
Comparison of SCT conditioning regimens
New evidence modified original recommendation B 2++ 42 (Table 6) There are not enough data to make a recommendation regarding the superiority of any one conditioning regimen. There appears to be a benefit to TBI-containing regimens compared to non-TBI-containing regimens. Reduced intensity conditioning may produce similar outcomes to myeloablative regimens, but available data are limited, thus reduced intensity regimens are appropriate only for patients with ALL in remission who are unsuited for myeloablative conditioning.
ALL indicates acute lymphoblastic leukemia; SCT, stem cell transplantation; LFS, leukemia-free survival; CR, complete remission; BM, bone marrow; TRM, treatment-related mortality; OS, overall survival; TBI, total-body irradiation. *Definitions for Grade of Recommendation (see Appendix A, Table 2 ): A 5 at least 1 meta-analysis, systematic review, or randomized controlled trial (RCT) rated as 1++, and directly applicable to the target population; or a systematic review of RCTs or a body of evidence consisting principally of studies rated as 1+, directly applicable to the target population, and demonstrating overall consistency of results; B 5 A body of evidence including studies rated as 2++, directly applicable to the target population, and demonstrating overall consistency of results; or extrapolated evidence from studies rated as 1++ or 1+; C 5 a body of evidence including studies rated as 2+, directly applicable to the target population and demonstrating overall consistency of results; or extrapolated evidence from studies rated as 2++; D 5 evidence level 3 or 4; or extrapolated evidence from studies rated as 2+. † Definitions for Levels of Evidence (see Appendix A, Table 1 ): 1++ High-quality meta-analyses, systematic reviews of randomized controlled trials (RCTs), or RCTs with a very low risk of bias; 1+ well-conducted meta analyses, systematic reviews of RCTs, or RCTs with a low risk of bias; 12 Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias; 2++ high-quality systematic reviews of case-control or cohort studies; or high quality case-control or cohort studies with a very low risk of confounding, bias, or chance and a high probability that the relationship is causal; 2+ Well conducted case-control or cohort studies with a low risk of confounding, bias, or chance, and a moderate probability that the relationship is causal; 22 Case-control or cohort studies with a high risk of confounding, bias, or chance, and a significant risk that the relationship is not causal; 3 Nonanalytic studies (eg, case reports, case series); 4 Expert opinion. ‡ The references listed represent the highest level of evidence used to make the treatment recommendation and are not inclusive of all evidence described in each section of the review. survival or OS among adult patients with T-lineage ALL in CR1 randomized to autologous SCT versus chemotherapy alone.
Donor versus No Donor
Goldstone et al. [6] also compared Philadelphia chromosome-negative (Ph-negative) patients in a donor versus no-donor analysis and reported a significant difference in 5-year OS in favor of standard risk Ph-negative patients with a donor versus no donor, but no difference in OS for high-risk Ph-negative patients. An unplanned subset analysis [10] reported the benefit of having a donor was greater in high-risk younger (\35 years) versus older patients; however, the difference was not significant.
Marks et al. [7] reported a significant benefit in 5-year OS for T-lineage ALL patients receiving sibling donor SCT versus no donor therapy (autologous SCT or chemotherapy); a difference that was maintained at 10 years.
Ribera et al. [8] reported no significant difference in 5-year DFS or OS between high risk patients with ALL in CR1 who had a donor versus those with no donor. Fielding et al. [11] found no significant difference in 5-year OS between Ph1 ALL patients in an intention-to-treat donor versus no-donor analysis; however, a significant difference in 5-year EFS and OS was reported in favor of Ph1 ALL patients whose actual treatment was an HLA-matched related or HLA-matched unrelated allogeneic SCT versus those who received chemotherapy alone.
Allogeneic SCT versus Chemotherapy ± Imatinib in Ph1/BCR-ABL1 ALL In a retrospective study by Li et al. [12] , Ph1 or BCR-ABL1 ALL patients who received chemotherapy combined with imatinib or underwent an HLAmatched related donor or HLA-compatible donor unrelated allogeneic SCT had significantly better 2-year DFS and 2-year OS compared with patients (preimatinib era) who received chemotherapy alone. Patients who underwent allogeneic SCT also had better survival outcomes than those in the chemotherapy 1 imatinib group, although there was no statistical significance.
In a prospective, multicenter study, Yanada et al. [13] reported no significant difference in 1-year OS between adult patients with BCR-ABL1 ALL who underwent an HLA-matched related or unrelated allogeneic SCT versus those who did not undergo transplantation, but received chemotherapy 1 imatinib or chemotherapy alone.
Original ALL EBR Studies
The six high-quality studies [14] [15] [16] [17] [18] [19] from the original adult ALL EBR provided seven analyses, including two randomized autologous SCT versus chemotherapy, two donor versus no donor, and three allogeneic bone marrow transplantation (BMT) versus chemotherapy for the treatment of adult ALL in CR1. The quality ratings of these studies ranged from 11 to 21. The majority of these studies reported no significant outcome differences; however, one study reported a donor versus no donor (autologous SCT or chemotherapy) advantage in 3-year DFS [18] . Another study reported a significantly better 5-year leukemiafree survival (LFS) in favor of an HLA-matched sibling allogeneic SCT versus chemotherapy alone, but only for patients #30 years of age [16] .
Transplantation versus Chemotherapy for Refractory or Relapsed Adult ALL Table 3 presents two studies published since the original ALL EBR, which compared transplantation versus chemotherapy as treatment for relapsed or refractory adult ALL.
Fielding et al. [20] reported a significantly better 5-year OS for adult patients with ALL in first relapse whose actual treatment was any type of SCT (HLAmatched sibling or HLA-matched unrelated allogeneic SCT or autologous SCT) versus those who received chemotherapy alone.
Cornillon et al. [21] reported a significant improved in 4-year OS for adult patients with refractory ALL who actually received an HLA-matched sibling allogeneic SCT versus chemotherapy or autologous SCT (based on donor availability).
There were no studies in the original adult ALL EBR that compared transplantation versus chemotherapy for refractory or relapsed ALL, or for ALL in CR2.
AUTOLOGOUS VERSUS ALLOGENEIC SCT FOR ADULT ALL
There were two studies published since the original ALL EBR, and briefly summarized below, which compared the outcomes of autologous versus myeloablative allogeneic SCT as treatment for adult ALL. The quality of these studies were 211 and 21. Table 4 summarizes the study designs, patient populations, and outcomes from this new evidence.
A donor (allogeneic SCT) versus no-donor (autologous SCT) analysis by Cornelisson et al. [22] reported a significantly better 5-year DFS for adult standard risk ALL patients with an HLA-matched related donor who underwent allogeneic SCT versus those without a donor who underwent autologous SCT.
Bishop et al. [23] found equivalent outcomes in 5-year LFS or OS for high-risk adult ALL patients in CR1 or CR2 who underwent an unrelated donor allogeneic SCT versus an autologous SCT. The details of one high-quality registry study (211) [24] and four multicenter studies (rated 21) [18, [25] [26] [27] , which were used to make a treatment recommendation in the original adult ALL EBR regarding the use of autologous SCT versus allogeneic SCT, are presented in Table 4 . All five studies found a significant improvement in DFS or LFS, and/or OS for patients who underwent an HLA-matched related or HLA-matched unrelated donor allogeneic SCT versus autologous SCT.
RELATED VERSUS UNRELATED ALLOGENIC SCT FOR ADULT ALL
There were five studies published since the original ALL EBR, and summarized briefly below, which compared related versus unrelated donor allogeneic SCT as treatment for adult patients with ALL. Table  5 presents a detailed summary of the study designs, patient populations, and outcomes from this new evidence, ranging in quality from 211 to 22. Recent and continuing improvements in unrelated donor HLA typing and selection impacting overall outcomes are not reflected in the earlier reports.
In a retrospective analysis of the Center for International Blood and Marrow Transplant Research data, Ringden et al. [28] reported no difference in 5-year LFS between adult ALL patients who underwent an HLA-matched sibling allogeneic SCT versus an HLA-matched unrelated donor allogeneic SCT.
In a retrospective analysis of single center data, Lee et al. [29] reported comparable 5-year DFS and 5-year OS in adult ALL patients who underwent an HLA-matched sibling donor allogeneic SCT versus an HLA-matched or mismatched unrelated donor allogeneic SCT.
Dahlke et al.
[30] reported comparable 3-year DFS and 3-year OS in older adult patients (58% $58 years) who underwent an HLA-matched or mismatched related allogeneic SCT versus an HLA-matched or mismatched unrelated donor allogeneic SCT.
In a long-term retrospective analysis of single center data, Chim et al. [31] reported significantly better 15-year DFS, but no difference in 15-year OS, in adult ALL patients who underwent an HLA-matched unrelated donor allogeneic BMT versus an HLA-matched sibling allogeneic BMT.
Cho et al.
[32] reported no significant difference in 3-year DFS or 3-year OS in a prospective, single center study of adult patients with ALL (majority in CR1) who underwent an HLA-matched sibling allogeneic SCT versus an HLA-matched or unmatched unrelated donor allogeneic SCT following a reduced-intensity conditioning (RIC) regimen.
In the original adult ALL EBR there was one multicenter study that compared related versus unrelated allogeneic SCT. Kiehl et al. [33] reported no significant difference in 5-year DFS in 221 patients with ALL in CR1 who underwent an HLA-matched related versus an HLA-matched unrelated allogeneic SCT (21 rating; not presented in Table 5 ).
OTHER COMPARATIVE STUDIES OF ADULT ALL
There were 12 comparative studies published since the original ALL EBR, and summarized briefly below, which investigated the impact of transplantationrelated factors, such as hematopoietic cell source (unrelated bone marrow versus cord blood, n 5 2 studies), pre-and/or post-SCT imatinib therapy (n 5 4 studies), induction therapy regimen (n 5 2 studies), induction versus no reinduction therapy (n 5 1 study), and conditioning regimen (n 5 3 studies) on survival outcomes in adult patients with ALL. Table 6 presents a detailed summary of the study designs, patient populations, and outcomes from this new evidence. The quality ratings of these 12 studies ranged from 111 to 21. There were no comparable studies in the original adult ALL EBR.
Unrelated Donor Bone Marrow (BM) versus Cord Blood SCT
Ferr a et al. [34] reported no significant difference in 5-year DFS or 5-year OS between adult high risk ALL patients who underwent an unrelated donor BMT versus a cord blood transplantation. Similarly, Atsuta et al. [35] reported no significant difference in 2-year LFS or 2-year OS between adult ALL patients who underwent an unrelated donor BMT versus a cord blood transplantation.
Imatinib versus No Imatinib Therapy
In a retrospective, registry analysis, Mizuta et al.
[36] reported significantly improved 3-year DFS and 3-year OS in adult Ph1 ALL patients who received imatinib therapy pre-and/or post-allogeneic SCT versus those in a preimatinib era historical control who did not. In a prospective, multicenter study, Bassan et al. [37] also reported significant improvement in 5-year DFS and 5-year OS in adult Ph1 ALL patients who received imatinib therapy pre-and/or post-SCT (autologous or allogeneic) versus those who did not receive imatinib. In addition, Lee et al. [38] reported significantly improved 3-year DFS and 3-year OS in adult Ph1 ALL patients who received imatinib therapy pre-and/or post-allogeneic SCT versus those in a preimatinib era historical control who did not. In a retrospective, single center study, Burke et al. [39] reported no significant difference in 2-year LFS or 2-year OS between adult Ph1 ALL patients who received imatinib therapy pre-and/or postallogeneic SCT versus those who did not receive imatinib or who received it only after relapse. 
Comparison of Induction Therapies
In a prospective, multicenter study Labar et al. [40] reported no significant difference in 6-year EFS or 6-year OS between adult ALL patients randomized to receive dexamethasone versus prednisolone as part of their induction therapy prior to receiving further chemotherapy or undergoing allogeneic or autologous SCT.
Wassman et al. [41] reported no significant difference in 2-year OS between adult patients with Ph1 ALL who received alternating or concurrent schedules of chemotherapy and imatinib as induction therapy prior to undergoing an allogeneic or autologous SCT.
Comparison of Reinduction versus NoReinduction Therapy for Refractory/Relapsed ALL
A retrospective analysis of a prospective, singlecenter treatment algorithm by Terwey et al. [42] found that adult patients with refractory or relapsed ALL who did not received reinduction chemotherapy prior to allogeneic SCT (31% received prophylactic donor lymphocytic infusions [DLI] starting after day 1 60) had significantly better 5-year OS than patients who did receive reinduction chemotherapy prior to allogeneic SCT (40% received prophylactic DLI).
Comparison of Conditioning Regimens
Marks et al. [43] reported no significant differences in 3-year DFS or 3-year OS, and Kojima et al. [44] reported no significant difference in 2-year OS, in comparisons of RIC versus myeloablative conditioning prior to allogeneic SCT in adult ALL patients.
In a retrospective analysis of two prospective trials, Deconinck et al. [45] reported significantly worse 4-year EFS and 4-year OS in patients who underwent an intensified versus standard dose induction, consolidation, and myeloablative conditioning regimen prior to allogeneic SCT, primarily because of an increased toxic death rate in the intensive protocol.
NONCOMPARATIVE STUDIES OF TRANSPLANTATION FOR ADULT ALL
There were 14 noncomparative cohort studies [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] published since the original EBR that examined the use of SCT as therapy for adult ALL. The design, methodology, and outcomes data from these noncomparative studies are summarized in Appendix B (online only). The studies represent nonrandomized single-or multi-institutional experiences with various transplantation techniques or retrospective analyses of transplant registry data. The quality of the noncomparative SCT studies ranged from 21 to 22. These noncomparative data on SCT for ALL provide additional, though lower level evidence, on SCT for ALL and thus are cited to provide added perspective on the published data.
AREAS OF NEEDED RESEARCH AND ONGOING STUDIES
After reviewing the updated evidence on the use of SCT for adult ALL, the expert panel identified several important areas of needed research. Some of these areas are being investigated by ongoing studies that are currently accruing patients, maturing follow-up, or which have been published in abstract form. The areas of needed research are grouped by topic, numbered, and followed by a brief description of some relevant ongoing studies, with some comment on their potential contribution to future treatment decisions. None of these studies were used as evidence for the review or for making treatment recommendations. This section is provided for the reader's information only.
Allogeneic SCT versus Chemotherapy 1. Reevaluate allogeneic SCT versus more intensive chemotherapy regimens, especially in younger (\35 years) adults, and in the context of biologic therapies and Tyrosine Kinase Inhibitors (TKIs) (for Ph1 ALL).
The ongoing studies summarized below follow a biologic allocation and comparison based upon donor availability in an attempt to perform a statistically randomized study that avoids bias. Intent-to-treat, donor versus no-donor comparisons avoid the bias of assessing only those with a donor and who were considered medically suitable to proceed with SCT; however, they can still result in confounding because of other types of SCT performed in those without a matched related donor.
A meta-analysis by Pidala et al. [60] consisted of aggregate outcome data from 14 trials and provided a donor versus no-donor comparison in 3215 adult patients to determine whether or not there is a survival benefit to allogeneic SCT for ALL in CR1.
Litzow et al. [61] presented the UKALLXII/E2993 trial on 1229 adult (14-65 years) Ph-negative B-ALL patients who were randomized to autologous SCT or to consolidation and maintenance chemotherapy. Patients \55 years of age with a matched sibling donor were biologically assigned to myeloablative allogeneic SCT. Analyses included chemotherapy versus autologous SCT and donor versus no-donor comparisons.
Leguay et al. [62] reported the outcomes of 75 young adult (15-59) with Ph-negative ALL. Of the 70 patients who attained CR, 54 (77%) were considered high risk and eligible for allogeneic SCT. Of these, 30 had a donor and received a SCT, and 24 received intensification and maintenance chemotherapy (donor/no-donor comparison). Of the remaining 16 patients in CR, two died before evaluation and 14 with low-risk ALL received chemotherapy alone followed by maintenance therapy.
A clinical trial (NCT00792948) sponsored by the Southwest Oncology Group is currently accruing patients to compare combination therapy (HyperCVAD 1 dasatinib) with or without allogeneic SCT for patients with Ph1 or BCR-ABL1 ALL. The estimated enrollment is 85 patients, and the primary clinical outcomes of interest are 1-year relapse-free survival and OS. This trial will provide preliminary estimates of efficacy, but future study of newer TKIs may yield better outcomes or identify situations where one agent, dose, or schedule is preferred.
Allogeneic SCT versus Chemotherapy ± TKI Therapy 2. Assess the ability of TKIs to reduce the leukemia murden pre-or post-SCT in Ph1 ALL patients and evaluate whether this can improve survival outcomes after autologous and allogeneic. Study of different TKIs, dose, and schedule will be important.
In a prospective, Northern Italy Leukemia Group study, Rambaldi et al. [63] investigated the clinical outcomes of adult Ph1 ALL patients who underwent allogeneic SCT (n 5 58) versus standard chemotherapy (n 5 33), or autologous SCT (n 5 9) with or without imatinib as part of induction/consolidation therapy.
Fielding et al. [64] reported the final results of the UKALLXII/COG2993 trial, comparing the outcomes of three nonrandomized subgroups of Ph1 ALL patients on imatinib versus no imatinib, early versus late imatinib, and allogeneic SCT versus chemotherapy maintenance including imatinib.
There are several ongoing clinical trials investigating SCT with or without TKI therapy. The Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) is sponsoring a phase II trial (NCT00458848) comparing the effectiveness of combination chemotherapy with or without imatinib and/or peripheral blood SCT for adult Ph1 ALL patients. The estimated enrollment is 253 patients, and the primary outcomes of interest are 1-year DFS and OS.
The Group for Research in Adult Acute Lymphoblastic Leukemia is sponsoring a randomized clinical trial (NCT00327678) comparing standard versus intensified induction for Ph-negative T or B ALL, rituximab versus no rituximab with or without allogeneic SCT for Ph-negative B ALL, and imatinib-based induction versus chemotherapy plus imatinib induction with or without allogeneic SCT based on donor availability and minimal residual disease status after induction for Ph1 ALL. The primary outcomes of interest are EFS and OS and the percentage of patients with minimal residual disease after induction or consolidation therapy. The estimated enrollment is 1080 patients.
A clinical trial (NCT01256398) sponsored by the Cancer and Leukemia Group B and the National Cancer Institute is investigating the use of dasatinib followed by allogeneic or autologous SCT as treatment for older ($50 years) adult patients with de novo Ph1 ALL. The estimated enrollment is 66 patients, and the primary outcome measure is 3-year DFS.
The Sheba Medical Center is sponsoring a clinical trial (NCT00750659) investigating the use of nilotinib pre-and post-allogeneic SCT for adult Ph1 ALL or advanced chronic myeloid leukemia patients. The estimated enrollment is 24 patients, and the primary measures are safety and response at one year.
Minimal Residual Disease (MRD)
3. Improvement in the detection and monitoring of MRD during initial treatment to guide individual patient eligibility and timing of allogeneic SCT.
In a Polish Adult Leukemia Group study (PALG 5-2007), Giebel et al. [65] compared the outcomes of 108 adult patients with ALL who received an individualized therapeutic approach with treatment intensity adjusted to MRD status and age, versus those from the PALG4-2002 trial in which MRD status was not taken into account for treatment decisions. In both studies, patients with standard risk ALL received induction/ consolidation followed by maintenance, whereas those with high-risk disease were referred for allogeneic SCT.
The Johann Wolfgang Goethe University Hospitals clinical trial (NCT00198991) is a multicenter study of treatment optimization in adult ALL based on the risk of relapse and MRD status. The primary outcomes measures are remission rate, remission duration, DFS, and OS. Secondary measures include realization of SCT, toxicity, and course of MRD. The estimated enrollment is 1250 patients.
4. Monitoring of MRD after SCT to detect early post-SCT relapse in need of preemptive therapy. This may indicate patients at higher risk of early recurrence, but effective therapy will also need to be developed.
Tang et al. [66] retrospectively analyzed the MRD status at day 1100 post-allogeneic SCT of 52 highrisk adult patients with ALL (n 5 25; acute myelogenous leukemia [AML], n 5 27) to evaluate the prognostic value of MRD pre-and post-SCT.
RIC for Allogeneic SCT
5. Indications for using RIC versus myeloablative conditioning regimens for allogeneic SCT. The broad range of conditioning intensity will need further study, adjusted for a patient's tolerance of conditioning toxicity balanced against the risk of relapse. It is likely that randomized comparative trials will be essential.
The Asan Medical Center is sponsoring a clinical trial (NCT01037764) of adult patients with ALL, comparing busulfan-cyclophosphamide versus busulfan-fludarabine-antithymocyte globulin conditioning regimens followed by BMT or peripheral blood stem cell transplantation (PBSCT), respectively, using HLA-matched sibling donors, HLA-matched unrelated donors, or HLA-mismatched related donors. Patients with an HLA-matched unrelated or mismatched related donor will receive the busulfanfludarabine-antithymocyte globulin conditioning and PBSCT. The outcome measures of interest include 3-year relapse rate, LFS, treatment-related mortality (TRM), and OS, and the estimated enrollment is 100 patients. Heterogeneity in patients, donor types, and disease risk status may confound conclusions in this modest sized trial.
Cord Blood Transplantation 6. Evaluation of cord blood transplantation techniques, such as single unit, double unit, and ex vivo expansion, to improve survival outcomes and reduce TRM. Larger multicenter experience will be needed to more fully evaluate the broader applicability of cord blood grafting for adults with ALL.
Brunstein et al. [67] investigated the effect of unrelated donor stem cell source on outcomes in adult ALL (n 5 62) or AML (n 5 523) patients, comparing PBSCT versus double cord blood transplantation after an RIC regimen.
Rocha et al. [68] compared acute leukemia patients (38% ALL, 62% AML) who underwent a double versus single cord blood transplantation in CR1, CR2, or CR3. The clinical outcome of interest was 3-year LFS and stratified by disease.
Post-SCT Patient Status and Management
Assessment of patient quality of life and functional status after successful SCT.
A clinical trial sponsored by the University Health Network, Toronto (NCT01148927) is evaluating the quality of life of long-term survivors of adult ALL who were treated with a modified Dana Farber Cancer Institute ALL protocol (91-01). Patients over 18, and who have completed the protocol at least three months prior and are in complete rmission are included. The patients complete several well-validated questionnaires assessing various quality of life issues of concern to these patients. Enrollment is estimated at 50 patients.
8. Assess the impact of management plans and follow-up care to facilitate better quality of life for ALL patients, regardless of treatment.
There are no ongoing studies specifically for ALL that address this area of needed research.
STRENGTHS/LIMITATIONS AND DISCUSSION
The strengths of this updated systematic evidencebased review are the details about each study's design and outcomes conveyed in the summary tables for each major section, and the consensus treatment recommendations made by the adult ALL expert panel.
A limitation is the exclusion of nonpeer-reviewed data. Unpublished data can represent ''negative'' findings that could lead to publication bias; however, the inclusion of high-quality, peer-reviewed publicly available data was of paramount importance. With the exception of the Ongoing Studies section, data published in abstract form were not included in this review because of the inadequate details of study design or patient characteristics, making a true assessment of the widespread applicability or impact of the treatment outside the scope of the trial difficult.
The quality of this systematic EBR is affected by treatment modalities that vary over time. Chemotherapy regimens, HLA typing techniques, novel pre-and post-SCT biologic and TKI therapies, and post-SCT supportive care change considerably over the course of these reviews and updates. The clinical research process is lengthy, making data from many of these studies outmoded by the time of publication. Much of the new data presented in this updated EBR may be obsolete in terms of the current standard of care, stressing the need for more timely updates of the EBRs. In addition, the lengthy process of conducting and reporting clinical research emphasizes the need to identify surrogate endpoints or molecular markers that are predictive of long-term survival in adult ALL patients. Further delineation of clinical risk factors may facilitate appropriate selection of ALL patients for SCT. In 1999, the American Society for Blood and Marrow Transplantation (ASBMT) began developing systematic evidence-based reviews (EBR) and position statements on the effectiveness of autologous and allogeneic hematopoietic stem cell transplantation (SCT) for specific diseases. The purpose of these reviews is to provide evidence in support of clinical decisions and matters of public policy regarding SCT and achieve broader and more consistent coverage from payers for established indications for SCT. The ASBMT EBR Steering Committee developed specific policies outlining the methodology to be followed for these reviews [1, 2] . Currently, eight reviews have been published in Biology of Blood and Marrow Transplantation (BBMT) on the use of SCT in the therapy of: diffuse large B cell lymphoma [3] , multiple myeloma [4] , pediatric acute lymphoblastic leukemia (ALL) [5] , adult ALL [6] , pediatric acute myeloid leukemia (AML) [7] , adult AML [8] , myelodysplastic syndromes [9] , and follicular lymphoma [10] .
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To achieve an appropriate balance, physicians who have extensive clinical experience and published research studies using SCT and other therapies in the treatment of the specific disease of interest are invited to join an independent expert panel that examines the summarized literature and provides subsequent treatment recommendations based on the available evidence. Potential panelists are restricted to U.S.-based institutions for two reasons: (1) ease of logistics in convening teleconferences, and (2) differences in the healthcare systems and health insurance coverage between the United States and other countries (including Canada, Europe, etc), which may result in different expert recommendations based on considerations of costs and access to care. In addition to clinical and research physicians, at least one third-party payer representative, a patient advocate, and a liaison to the ASBMT Steering Committee are invited to serve on the panel.
Literature Search Methodology for the Adult All EBR Update
The SCOPUS database, which includes PubMed and Medline, the Websites developed by the National Center of Biotechnology Information at the National Library of Medicine of the National Institutes of Health, were first searched on July 29, 2010, using the search terms ''acute lymphoblastic leukemia'' OR ''ALL'' AND ''transplant'' limited to ''human trials,'' ''English language,'' and a publication date of January 1, 2005 or later. An updated search was conducted on October 15, 2010. In addition to the online database searches, a manual search of the reference lists of the included articles and relevant reviews published since January 2005 was conducted.
Papers that were published before January 2005, included fewer than 25 ALL patients, or were not peer-reviewed were excluded. Also excluded were editorials, letters to the editor, Phase I (dose escalation or dose finding) studies, reviews, consensus conference papers, practice guidelines, and laboratory studies with no clinical correlates. Abstracts and presentations at national or international meetings were not used for the treatment recommendations in this update for reasons previously described [5] . However, abstracts are included in the ''Areas of Needed Research and Ongoing Studies'' section for the reader's information.
Several of the studies evaluated for inclusion in this adult ALL update included patients with AML; therefore, to be included, at least 65% of a study's patients had to have ALL, unless the results were stratified by disease.
Qualitative and Quantitative Grading of the Evidence
The hierarchy of evidence, including a grading system for the quality and strength of the evidence and strength of each treatment recommendation, was published as an editorial policy statement in BBMT in 2005 [2] . Appendix A, Tables 1 and 2 , reprinted from the policy statement, define criteria used to grade the studies that were included in this update and criteria to grade the treatment recommendations, respectively. Study design, including sample size, patient selection criteria, duration of follow-up, and treatment protocol also were considered in evaluating the studies. Clinical studies are described in the tables with sufficient detail to give a concise summary of study design and patient outcomes.
All data in the text and tables were abstracted from the original manuscripts by the first author (D.O.) and double checked for accuracy and clarity by 2 other authors (T.H. and P.L.M.). Some articles contained inconsistencies within the data reported; the data most consistent with the text of the article were included in this review.
Format of the Adult All EBR Update
Evidence is taken from studies published after January 2005 of adult ALL patients. For each section of the review, a summary paragraph provides an overall description of the number and types of studies included as evidence, as well as a brief synopsis of outcomes. As noted earlier, unlike the original ALL EBRs, in which each article was summarized in detail in the text, this update presents the study design, patient population, and clinical outcomes only in the detailed summary tables.
The highest quality studies are presented in the tables first, while studies of equal quality are presented in descending order by study population size. Individual studies that were also included in a metaanalysis are identified in the tables. New evidence is provided first in each table, followed by the highest quality studies (ratings from 111 to 211) used to make treatment recommendations in the original adult ALL EBR. Both Level 1 and Level 2 evidence is presented in the tables for each study that provided biologic assignment (donor versus no donor) and randomized (autologous SCT versus chemotherapy) results. When specific data elements of a study's patient population or disease characteristics were not included in a table, it was because the information was not provided in the article.
Consensus Process for Treatment Recommendations
The Treatment Recommendations Table (Table 1 in the Adult ALL EBR Update) contains the summary of consensus treatment recommendations made by the expert panel based on the summarized evidence. The consensus process involves a teleconference during which panelists critically discuss the evidence for each section of the review and develop initial treatment recommendations according to the categories in Appendix A, Table 2 . The information is summarized by the primary authors in the Treatment Recommendations Table and distributed to the panelists for additional review and clarification. Any changes suggested by an individual panelist are circulated for review and approval by all panelists. This iterative process concludes when a final version of the Treatment Recommendations Table is approved by all panelists.
After the final draft of the Adult ALL EBR Update is approved by the expert panel it is reviewed by the ASBMT EBR Steering Committee and then submitted to the BBMT journal for peer-review. Any changes requested during the peer-review process must be reviewed and approved by all the expert panelists.
